drj logo
  • This field is for validation purposes and should be left unchanged.

Already have an account? Log in

drj logo

Welcome to DRJ

Already registered user? Please login here

Login Form

Register
Forgot password? Click here to reset

Create new account
(it's completely free). Subscribe

Skip to content
Disaster Recovery Journal
  • EN ESPAÑOL
  • SIGN IN
  • SUBSCRIBE
  • THE JOURNAL
    • Young Professional Spotlight
    • Career Spotlight
    • Article Submission
    • Digital Edition
    • DRJ Annual Resource Directories
    • Article Archives
  • EVENTS
    • DRJ Fall 2022
    • Other Industry Events
    • Schedule & Archive
  • WEBINARS
    • Upcoming Webinars
    • On Demand
  • MENTOR PROGRAM
  • DRJ ACADEMY
    • DRJ Academy
    • Beginner’s Guide to BC
  • RESOURCES
    • New to Business Continuity?
    • White Papers
    • DR Rules and Regs
    • Planning Groups
    • Business Directory
    • Business Resilience Decoded
    • DRJ Glossary of Business Continuity Terms
    • Careers
  • ABOUT
    • Advertise with DRJ
    • Board and Committees
      • Executive Council Members
      • Editorial Advisory Board
      • Career Development Committee
      • FAQs Committee
      • Web Committee
      • Glossary Committee
      • Rules and Regulations Committee
  • Podcast

Siemens Healthineers Announces FDA Emergency Use Authorization For CLINITEST® Rapid COVID-19 Antigen Self-Test

by DRJ Editorial Team | December 29, 2021 | | 0 comments

  • The CLINITEST Rapid COVID-19 Antigen Self-Test has received FDA EUA for unsupervised self-testing for the SARS-CoV-2 virus by individuals age 14 and older (or adult-collected samples from individuals ages 2-13).
  • Rapid antigen testing provides results in just 15 minutes and the information can help reduce the risk of COVID-19 exposure.
  • Through nationwide retail distribution, the new self-test will be made broadly available as COVID-19 testing needs continue to grow for individuals, families, and businesses.

TARRYTOWN, N.Y.–(BUSINESS WIRE)–Siemens Healthineers announces that the U.S. Food and Drug Administration (FDA) today granted Emergency Use Authorization (EUA) for the CLINITEST Rapid COVID-19 Antigen Self-Test,1, 2, 3 providing nationwide access to a new at-home or over-the-counter self-test as COVID-19 testing needs continue to grow for individuals, families, and businesses. The easy-to-use nasal swab test is intended to aid in the rapid detection of SARS-CoV-2 (the virus that causes COVID-19) and provides visually read test results in just 15 minutes. It is authorized for self-testing use by individuals age 14 and older or adult-collected samples from individuals ages 2 to 13 years. The test is expected to be available starting in January. Siemens Healthineers has secured dedicated production capacity for U.S. bound product in the tens of millions per month.


“Undetected COVID-19 exposure is a major driver of community spread. With the CLINITEST Rapid COVID-19 Antigen Self-Test, consumers will have access to a fast, reliable, and convenient test to provide additional safety,” said Christoph Pedain, PhD, Head of Point of Care Diagnostics, Siemens Healthineers. “Siemens Healthineers is proud to bring this high-quality test, already used and trusted by families, medical professionals, businesses and governments in many parts of the world, to the United States under FDA Emergency Use Authorization.”

The product comes in a specific configuration for the United States and has been evaluated in a study specifically designed for the U.S. market and fully conducted in the U.S. with laypersons, thereby covering currently circulating variants of SARS-CoV-2. Meeting the high threshold of the US FDA, the product is highly accurate, with sensitivity of 86.5% (95% CI: 79.6 to 91.3%) and a specificity of 99.3% (95% CI: 95.9 to 100.0%) compared to the nucleic acid (PCR) detection method. Sensitivity defines the test’s ability to produce a positive result in those infected with SARS-CoV-2 per the PCR reference method, and specificity defines the ability to produce a negative result in those not currently infected with SARS-CoV-2.

All clinical data has been established under Siemens Healthineers participation in the National Institutes of Health (NIH) Rapid Acceleration of Diagnostics’ (RADx) Independent Test Assessment Program (ITAP).

“The CLINITEST Rapid COVID-19 Antigen Self-Test detects SARS-CoV-2 antigens in people who are actively infected with the virus, making important information more readily available,” added Dr. Pedain. “We’d like to thank the U.S. Government, specifically the National Institutes of Health Rapid Acceleration of Diagnostics’ Independent Test Assessment Program, for their partnership in bringing much needed tests to the American people. We know this is a critical time in this pandemic, and we will do our part in providing support.”

Reliable results can help consumers make confident, informed decisions about their daily lives, with the simplicity of a nasal swab test at home. Consumers who receive a positive test result should follow guidance from the Centers for Disease Control and Prevention (CDC) to isolate and take steps to mitigate the spread of COVID-19.

Siemens Healthineers response to the pandemic

Siemens Healthineers has distinguished itself as a provider of quality diagnostic assays to aid the fight against the COVID-19 pandemic. In addition to antibody, antigen, and molecular SARS-CoV-2 tests, Siemens Healthineers offers a broad diagnostics portfolio across point of care and laboratory applications to aid in the prognosis, treatment and follow-up of COVID-19 patients. The company’s broad and differentiated menu includes hematology, coagulation, cardiac, respiratory, inflammation and infectious disease panels. Blood gas testing and imaging solutions from Siemens Healthineers deliver actionable results that aid clinicians in caring for COVID-19 patients.

For further information on the CLINITEST Rapid COVID-19 Antigen Self-Test, please visit www.clinitest.siemens-healthineers.com/US.

1 Product availability varies by country. Distributed by Siemens Healthineers.

2 The FDA’s EUA decision is based on the company’s participation in the NIH Rapid Acceleration of Diagnostics’ (RADx) Independent Test Assessment Program (ITAP), which aims to accelerate the regulatory review and availability of high-quality, accurate and reliable OTC test to the American public.

3 In the USA, this product has not been FDA cleared or approved; but has been authorized by FDA under an Emergency Use Authorization. This product has been authorized only for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens. The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.

Siemens Healthineers AG (listed in Frankfurt, Germany: SHL) pioneers breakthroughs in healthcare. For everyone. Everywhere. As a leading medical technology company headquartered in Erlangen, Germany, Siemens Healthineers and its regional companies is continuously developing its product and service portfolio, with AI-supported applications and digital offerings that play an increasingly important role in the next generation of medical technology. These new applications will enhance the company’s foundation in in-vitro diagnostics, image-guided therapy, in-vivo diagnostics, and innovative cancer care. Siemens Healthineers also provides a range of services and solutions to enhance healthcare providers’ ability to provide high-quality, efficient care. In fiscal 2021, which ended on September 30, 2021, Siemens Healthineers, which has approximately 66,000 employees worldwide, generated revenue of €18.0 billion and adjusted EBIT of €3.1 billion. Further information is available at www.siemens-healthineers.com.

Contacts

For Journalists
Trade media:

Lance Longwell

Phone: +1 610-883-0788; Email: lance.longwell@siemens-healthineers.com

Business and financial media:

Ulrich Kuenzel

Phone: +49 162 2433492; Email: ulrich.kuenzel@siemens-healthineers.com

Recent Posts

  • Download Your Planning Templates
  • They Called Me ‘The Queen of Doom’
  • Business Continuity as a Business Strategy
  • AlertMedia Improves Emergency Management with the Launch of Event Pages: Connecting People with Critical Information in Real-Time
  • Disaster Recovery Planning in a VM Operating Environment

Recent Comments

  • carybaron@yahoo.com on Contingency Planning Cycle
  • marifergerson0102 on Contingency Planning Cycle

Archives

  • December 2020 (1)
  • October 2020 (1)
  • August 2020 (1)
  • January 2020 (1)
  • November 2019 (9)
  • October 2019 (8)
  • September 2019 (8)
  • August 2019 (17)
  • July 2019 (77)
  • June 2019 (92)
  • May 2019 (128)
  • April 2019 (109)
  • March 2019 (80)
  • February 2019 (106)
  • January 2019 (102)
  • December 2018 (96)
  • November 2018 (131)
  • October 2018 (139)
  • September 2018 (81)
  • August 2018 (124)
  • July 2018 (113)
  • June 2018 (90)
  • May 2018 (142)
  • April 2018 (151)
  • March 2018 (124)
  • February 2018 (157)
  • January 2018 (140)
  • December 2017 (118)
  • November 2017 (158)
  • October 2017 (186)
  • September 2017 (139)
  • August 2017 (212)
  • July 2017 (179)
  • June 2017 (214)
  • May 2017 (230)
  • April 2017 (223)
  • March 2017 (159)
  • February 2017 (175)
  • January 2017 (112)
  • December 2016 (8)
  • October 2016 (12)
  • June 2016 (15)
  • May 2016 (4)
  • April 2016 (10)
  • January 2016 (10)
  • December 2015 (2)
  • October 2015 (12)
  • September 2015 (2)
  • June 2015 (15)
  • April 2015 (15)
  • March 2015 (6)
  • February 2015 (7)
  • January 2015 (6)
  • December 2014 (18)
  • November 2014 (19)
  • October 2014 (24)
  • September 2014 (11)
  • August 2014 (13)
  • July 2014 (7)
  • June 2014 (36)
  • May 2014 (19)
  • April 2014 (21)
  • March 2014 (90)
  • February 2014 (5)
  • January 2014 (26)
  • December 2013 (10)
  • November 2013 (25)
  • October 2013 (37)
  • September 2013 (27)
  • August 2013 (8)
  • July 2013 (8)
  • June 2013 (31)
  • May 2013 (17)
  • April 2013 (103)
  • March 2013 (82)
  • February 2013 (120)
  • January 2013 (212)
  • December 2012 (128)
  • November 2012 (92)
  • October 2012 (159)
  • September 2012 (112)
  • August 2012 (153)
  • July 2012 (106)
  • June 2012 (91)
  • May 2012 (35)
  • April 2012 (49)
  • March 2012 (14)
  • February 2012 (19)
  • January 2012 (44)
  • December 2011 (9)
  • November 2011 (21)
  • October 2011 (45)
  • September 2011 (13)
  • August 2011 (9)
  • July 2011 (47)
  • May 2011 (46)
  • April 2011 (10)
  • March 2011 (25)
  • February 2011 (1)
  • January 2011 (17)
  • December 2010 (8)
  • October 2010 (19)
  • September 2010 (1)
  • July 2010 (23)
  • June 2010 (1)
  • May 2010 (1)
  • April 2010 (21)
  • March 2010 (1)
  • February 2010 (1)
  • January 2010 (4)
  • December 2009 (20)
  • November 2009 (4)
  • October 2009 (17)
  • September 2009 (11)
  • August 2009 (2)
  • July 2009 (2)
  • June 2009 (79)
  • April 2009 (20)
  • March 2009 (1)
  • January 2009 (22)
  • November 2008 (1)
  • October 2008 (1)
  • July 2008 (4)
  • June 2008 (22)
  • April 2008 (25)
  • February 2008 (1)
  • January 2008 (16)
  • December 2007 (17)
  • November 2007 (662)
  • October 2007 (410)
  • September 2007 (1)
  • November 1999 (1)

ARTICLES & NEWS

  • Business Continuity
  • Disaster Recovery
  • Crisis Management & Communications
  • Risk Management
  • Article Archives
  • Industry News

THE JOURNAL

  • Digital Edition
  • Young Professionals
  • Career Spotlight
  • Advertising & Media Kit
  • Submit an Article

RESOURCES

  • White Papers
  • Rules & Regulations
  • FAQs
  • Glossary of Terms
  • Industry Groups
  • Business & Resource Directory
  • Business Resilience Decoded

EVENTS

  • Fall 2022
  • Spring 2022

WEBINARS

  • Watch Now
  • Upcoming

CONTACT

  • Article Submission
  • Media Kit
  • Contact Us

ABOUT DRJ

Disaster Recovery Journal is the industry’s largest resource for business continuity, disaster recovery, crisis management, and risk management, reaching a global network of more than 138,000 professionals. Offering weekly webinars, the latest industry news, rules and regulations, podcasts, the industry’s only official mentoring program, a quarterly magazine, and two annual live conferences, DRJ is leading the way to keep professionals up-to-date and connected in an ever-changing world.

LEARN MORE

TWITTER

Disaster Recovery Journal is the leading publication/event covering business continuity/disaster recovery.

Follow us for daily updates @drjournal

Newsletter

The Journal, right in your inbox.

Be informed and stay connected by getting the latest in news, events, webinars and whitepapers on Business Continuity and Disaster Recovery.

Subscribe Now
Copyright 2022 Disater Recovery Journal
  • Terms of Use
  • Privacy Policy